Evidence map›Paper›PMID 30448733›Full record

ArticleTranslational oncology2019

miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis.

Matteo Fassan, Ri Cui, Pierluigi Gasparini, Claudia Mescoli, Vincenza Guzzardo, Caterina Vicentini, Giada Munari, Fotios Loupakis, Sara Lonardi, Chiara Braconi and 13 more

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 4 countries.

Matteo FassanDepartment of Medicine (DIMED), University of Padua, Padua, Italy.
Ri CuiHuman Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Pierluigi GaspariniHuman Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Claudia MescoliDepartment of Medicine (DIMED), University of Padua, Padua, Italy.
Vincenza GuzzardoDepartment of Medicine (DIMED), University of Padua, Padua, Italy.
Caterina VicentiniARC-NET Research Center, University of Verona, Verona, Italy.
Giada MunariDepartment of Medicine (DIMED), University of Padua, Padua, Italy.
Fotios LoupakisOncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy.
Sara LonardiOncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, Italy.
Chiara BraconiCancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK; Department of Medicine, The Royal Marsden NHS Trust, London, UK.
Marco ScarpaDepartment of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
Edoardo D'AngeloDepartment of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
Salvatore PucciarelliDepartment of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
Imerio AngrimanDepartment of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
Marco AgostiniDepartment of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
Renata D'IncáDepartment of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
Fabio FarinatiDepartment of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy.
Roberta GafàDepartment of Pathology, University of Ferrara, Ferrara, Italy.
Giovanni LanzaDepartment of Pathology, University of Ferrara, Ferrara, Italy.
Wendy L FrankelDepartment of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Carlo Maria CroceHuman Cancer Genetics Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Nicola ValeriDepartment of Medicine, The Royal Marsden NHS Trust, London, UK; Molecular Pathology Division, Institute of Cancer Research, London and Sutton, UK. Electronic address: nicola.valeri@icr.ac.uk.
Massimo RuggeDepartment of Medicine (DIMED), University of Padua, Padua, Italy.
University of Padua · ITIstituto Oncologico Veneto · ITUniversity of Ferrara · ITUniversity of Verona · ITCancer Genetics (United States) · USInstitute of Cancer Research · GBThe Ohio State University · USWenzhou Medical University · CN

Funding

Cancer Research UK 18052Cancer Research UK A18052
6 · The paper itself

Abstract

miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive colorectal lesions was investigated for miR-224 expression by qRT-PCR and in situ hybridization. The caspase-3 and caspase-7 status was also assessed and correlated to miR-224 dysregulation. miR-224 was significantly upregulated during the adenoma-carcinoma sequence and in the context of inflammatory bowel disease dysplastic lesions, whereas its expression was significantly downregulated among BRAF-mutated tumors and in the presence of a DNA mismatch repair deficiency. miR-224 targets caspase-3 and caspase-7 in colorectal cancer, and this inverse relation was already evident from the earliest phases of transformation in intestinal mucosa. The miR-224/caspases axis may represent an interesting field of study for innovative biomarkers/therapeutics for BRAF-mutated/DNA mismatch repair-deficient tumors.

Identifiers

PMID30448733
PMCPMC6240712
OpenAlexW2901651432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.